Skip to main content
Clinical Trials/NCT04665232
NCT04665232CompletedNot Applicable

Immunomodulatory Effects of Subcutaneous Progesterone in Patients Undergoing IVF Affected by Autoimmune Diseases

San Carlo Public Hospital, Potenza, Italy1 site in 1 country18 target enrollmentStarted: April 2014Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
18
Locations
1
Primary Endpoint
Pregnancy Rate percentage, Implantation Rate percentage, Live Birth Rate percentage

Study Overview

Brief Summary

This study evaluates the immunomodulatory effects of subcutaneous progesterone in patients undergoing IVF by determination of anti-nuclear antibodies (ANA),extractable nuclear antigen antibodies (ENA),anti- neutrophil cytoplasmic antibodies(ANCA),anti-DNA antibodies, anti-cardiolipin antibodies (ACA),Lupus anticoagulant antibodies (LAC) and C3 and C4 fractions of complement on the day of beta hCG dosage and during the eigth week of gestation.

Detailed Description

The aqueous progesterone preparation for s.c. injection is the first systemic progesterone of its kind for the provision of luteal phase support (LPS) in patients undergoing IVF.

The the high solubility and rapid absorption of the new preparation are enhanced using cyclodextrins that are starch residues with no therapeutic activity and with a particular molecular structure that closely resembles a 'cap'.

Once absorbed after injection, the progesterone molecule is immediately dissociated from its cyclodextrin 'cap', remaining free in the circulation as if produced endogenously by the ovaries.

In comparison to progesterone-in-oil preparation, the new aqueous solution administered by s.c.route resulted in a 3 fold higher and more rapid progesterone peak serum concentrations.

The immunomodulating effects of progesterone are mediated outside of the pelvic cavity, on the peripheral cell of the immune system. For this reason only the injection procedure has this advantage Furthermore, the faster absorption rate and the higher peak serum concentration should increas the systemic immunomodulatory effect of subcutaneous progesterone compared to the vaginal and intramuscular administration

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 42 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Infertile patients affected by autoimmune diseases undergoing IVF

Exclusion Criteria

  • infertile patients without autoimmune diseases, fertile patients affected by autoimmune diseases

Arms & Interventions

Patients affected by autoimmune diseases

Infertile patients suffering from autoimmune diseases to be subjected to IVF in which the luteal phase has been supplemented with 25 mg /die of aqueous subcutaneous progesterone

Intervention: aqueous subcutaneous progesterone (Drug)

Outcomes

Primary Outcomes

Pregnancy Rate percentage, Implantation Rate percentage, Live Birth Rate percentage

Time Frame: 12 mounths

number of pregnancies / 100 embryotransfer, number of implanted embryos/ number of embryos trafsferred, number of live birth

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
San Carlo Public Hospital, Potenza, Italy
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Assunta Iuliano, MD

MD, PhD

San Carlo Public Hospital, Potenza, Italy

Study Sites (1)

Loading locations...

Similar Trials